
Country Demographics <sup>1,2,10</sup>				
Total population (2020) 10	168,775			
Urban population (% of total, 2020) <sup>1</sup>	95%			
Health expenditure per capita (\$US, 2012) <sup>2</sup>	NR			
Health expenditure, total (% of GDP, 2012) <sup>2</sup>	NR			
Total births (2019) <sup>1</sup>	2,753			
Surviving infants (2019) <sup>1</sup>	2,730			
Life expectancy at birth (years, 2017) <sup>2</sup>	79.8 yrs			
Number of districts (2013) <sup>3</sup>	0			


HBsAg Prevalence <sup>6</sup>	
Pre-vaccine HBsAG+ (%)	4%

Liver Cancer as Cause of Cancer	r Death (in Men) <sup>5</sup>
Year: 2018	Ranking: 2

2019 Country Comparison in Western Pacific Region (37 Member States/Areas) <sup>4</sup>							
	Guam	Number of member states with WHO-UNICEF estimated coverage	Highest WHO-UNICEF estimated coverage in WPR	Lowest WHO-UNICEF estimated coverage in WPR			
HepB3⁴	NR	27	99% (Brunei Darussalam, China, Fiji, Japan, Niue, Tonga)	35% (Papua New Guinea)			
HepB BD <sup>4</sup>	NR	24	99% (Brunei Darussalam, Cook Islands, Fiji, Kiribati, Malaysia, Nauru, Niue, Palau, Tonga)	25% (Papua New Guinea)			

Hepatitis	epatitis B Immunization Coverage <sup>4,7,8</sup> *These are official country estimates, not WHO-UNICEF estimates.																			
	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
HepB3 <sup>7</sup>	94%	84%	78%	77%	85%	88%	91%	NR	NR	NR	NR	NR	38%	NR	NR	94.6%	85.8%	83% <sup>8</sup>	NR <sup>4</sup>	NR
HepB BD <sup>7</sup>	99%	99%	99%	99%	99%	98%	97%	100%	98.7%	100%	NR	NR	100%	100%	100%	87.7%	85.5%	80%8	NR <sup>4</sup>	NR
DTP3 <sup>7</sup>	92%	84%	87%	88%	87%	86.4%	89%	NR	NR	NR	NR	NR	49%	NR	NR	91%	NR	NR	NR <sup>4</sup>	NR
BCG <sup>7</sup>	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR <sup>4</sup>	NR








Abbreviations: NA= not applicable; NR= no report; HepB BD= birth dose within 24 hours; HepB3= at least 3 doses of HepB vaccine; HBsAg= HepB surface antigen. Data Compiled by APAVH 2020: WHO WPRO Hepatitis B control: country profile 2019<sup>1</sup>, World DataBank: World Development Indicators database<sup>2</sup>, NationMaster Country Profiles<sup>3</sup>, WHO Vaccine-Preventable Diseases: Monitoring System. 2020 global summary Official Country Estimates<sup>4</sup>, Global Cancer Observatory: Cancer Today-IARC<sup>5</sup>, Western Pacific Regional Plan for Hepatitis B control through Immunization<sup>6</sup>, WHO West Pacific Region Health Information and Intelligence Platform (HIIP): Immunization Coverage<sup>7</sup>, Progress Toward Hepatitis B Control and Elimination of Mother-to-Child Transmission of Hepatitis B Virus — Western Pacific Region, 2005–2017<sup>8</sup>, National Immunization Data — EPI summaries by country<sup>3</sup>, Worldometer, Guam 2020<sup>10</sup>



National Policies on Hepatitis B Immunization <sup>9</sup>					
Universal newborn HepB immunization (Y/N) <sup>9</sup>	Υ				
- If Y, year introduced <sup>9</sup>	1989				
-HepB3 nationwide <sup>9</sup>	NR				
-Free for all newborns (Y/N)					
-If free, state year introduced:					
Catch-up immunization program for unvaccinated children (Y/N)					
- If Y, year introduced					
-Free for all unvaccinated children (Y/N)					
-If free, state year introduced:					
Immunization program for health care workers (Y/N)					
- If Y, year introduced					
-Free for all health care workers(Y/N)					
-If free, state year introduced:					
HepB newborn immunization included in multiyear plan for EPI (Y/N)					
HepB BD in schedule (Y/N) <sup>9</sup>	Y				
Systems to monitor HepB BD <sup>9</sup>	Hospitals				
Systems to deliver HepB BD <sup>9</sup>	Hospitals				
HepB vaccine funding other than country government (Y/N)					
-If Y, please specify funding source:					



National Policies on Chronic Hepatitis B Treatment						
Treatment for chronic HBV infection covered (Y/N)						
- If Y, year introduced						
-Interferon (Y/N)						
-Oral antiviral (Y/N)						

Certification Status <sup>1</sup>	
Year certification report received	
Year certification panel convened	Oct 2015
Year certification approved	Jun 2016
Approved with prevalence <1% or <2%?	<1% in children

